All In Biotech

Drug Trial Radar · NCT02901288

Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis

Shortened Regimens for First Diagnosed Smear Positive Drug Susceptible Pulmonary Tuberculosis: a Randomised Controlled Non-inferiority Trial

Last checked: Nov 19, 2026Latest source record: Mar 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 3,900 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

3,900

Planned (sponsor's estimate)

Start

Aug 2016

Primary completion

Dec 2018

Study completion Dec 2018

Sponsor

Lead sponsor
Beijing Chest HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hubei Provincial Center for Disease Control and Prevention; Centre for Tuberculosis Control of Guangdong Province; Hunan Institute For Tuberculosis Control; Anhui Chest Hospital; Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control; Wuhan Institute for Tuberculosis Control; Shanghai Pulmonary Hospital, Shanghai, China; Shenyang Chest Hospital; Changchun Infectious Disease Hospital; First Affiliated Hospital of Xinjiang Medical University; Chengdu Public Health Clinical Center; Taiyuan Fourth People's Hospital; The Sixth People's Hospital of Nantong; The Tuberculosis Prevention and Treatment Hospital of Shanxi Province; Beijing Research Institute for Tuberculosis Control; Infectious Disease Prevention Hospital in Heilongjiang Province; The Third People's Hospital of Zhenjiang; Tianjin centers for Disease Control and Prevention; Harbin Chest Hospital; Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC; Heilongjiang Province center for tuberculosis Control and Prevention; Tianjin Haihe Hospital; The Infectious Disease Hospital of Wangkai Zaozhuang; The Third People's Hospital of Kunming City; Kaifeng Central Hospital; The Infectious Hospital of Hebi; Pulmonary Hospital of Lanzhou; The Fourth People's Hospital of Ningxia Autonomous Region; The Fourth People's Hospital of Qinghai Province; The Fifth People's Hospital of Suzhou; Chongqing Infectious Disease Medical Center; Tuberculosis Hospital in Jilin Province; Sixth People's Hospital of Nanyang City; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
First posted
Sep 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety and efficacy of two shortened regimens for newly diagnosed smear positive drug susceptible pulmonary tuberculosis in comparison to World Health Organization recommended standard 6-month regimen.

Conditions

  • Tuberculosis, Pulmonary

Interventions

  • IsoniazidDrug

    Isoniazid is a widely used anti-tuberculosis medication. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique components of mycobacterial cell wall.

  • RifampicinDrug

    Rifampicin is a widely used anti-tuberculosis medication.

  • PyrazinamideDrug

    Pyrazinamide is a commonly used medication for tuberculosis, with bactericidal effect against intracellular mycobacterium tuberculosis.

  • EthambutolDrug

    Ethambutol is a widely used medicine in anti-TB regimens with bacteriostatic effect against M. tb.

  • LevofloxacinDrug

    Levofloxacin is a commonly used antimicrobial for TB and other infections, which acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of participants with TB recurrence/relapse by 24 months after the end of treatment.Time frame: 24 months after treatment completion for all 3 groups
  2. Percentage of participants with treatment failure at either 4.5 months or 6 months after randomization.Time frame: 4.5 months after randomization for experimental group1 and 2; 6 months after randomization for control group

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Chest Hospital

    Hefei, Anhui, China · Recruiting

  • Beijing Research Institute for Tuberculosis Control

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Chest Hospital,Capital Meical University

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing Infectious Disease Medical Center

    Chongqing, Chongqing Municipality, China · Recruiting

  • Pulmonary Hospital of Lanzhou

    Lanzhou, Gansu, China · Recruiting

  • Centre for Tuberculosis Control of Guangdong Province

    Guangzhou, Guangdong, China · Recruiting

  • Guangxi Center for Disease Prevention and Control

    Nanning, Guangxi, China · Recruiting

  • HeBei Province Center for Disease Prevention and Control

    Shijiazhuang, Hebei, China · Recruiting

  • Heilongjiang Province center for tuberculosis Control and Prevention

    Haerbin, Heilongjiang, China · Recruiting

  • Harbin Chest Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Infectious Disease Prevention Hospital in Heilongjiang Province

    Harbin, Heilongjiang, China · Recruiting

  • The Infectious Hospital of Hebi

    Hebi, Henan, China · Recruiting

  • Kaifeng Pulmonary Disease Hospital

    Kaifeng, Henan, China · Recruiting

  • Sixth People's Hospital of Nanyang City

    Nanyang, Henan, China · Recruiting

  • The First Affiliated Hospital of Xinxiang Medical University

    Xianxiang, Henan, China · Recruiting

  • Wuhan medical treatment center

    Wuhan, Hubei, China · Recruiting

  • Wuhan Institute For Tuberculosis Control

    Wuhan, Hubei, China · Recruiting

  • Hunan Institute For Tuberculosis Control

    Changsha, Hunan, China · Recruiting

  • The Sixth People's Hospital of Nantong

    Nantong, Jiangsu, China · Recruiting

  • The Fifth People's Hospital of Suzhou

    Suzhou, Jiangsu, China · Recruiting

  • The Third People's Hospital of Zenjiang

    Zhenjiang, Jiangsu, China · Recruiting

  • Changchun Infectious Disease Hospital

    Changchun, Jilin, China · Recruiting

  • Tuberculosis Hospital in Jilin Province

    Jilin City, Jilin, China · Recruiting

  • China Shenyang Chest Hospital

    Shenyang, Jilin, China · Recruiting

  • The Fourth People's Hospital of Ningxia Autonomous Region

    Yinchuan, Ningxia, China · Recruiting

  • The 4th People's Hospital of Qinghai Province

    Xining, Qinghai, China · Recruiting

  • The Infectious Disease Hospital of Wangkai Zaozhuang

    Tengzhou, Shandong, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Taiyuan Fourth People's Hospital

    Taiyuan, Shanxi, China · Recruiting

  • The Tuberculosis Prevention and Treatment Hospital of Shanxi Province

    Xi’an, Shanxi, China · Recruiting

  • Public Health Clinical Center of Chengdu

    Chengdu, Sichuan, China · Recruiting

  • Tianjin Haihe Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Tianjin centers for Disease Control and Prevention

    Tianjin, Tianjin Municipality, China · Recruiting

  • Chest of Hospital of Xinjiang Uygur Autonomous Region of the PRC

    Ürümqi, Xinjiang, China · Recruiting

  • The Third People's Hospital of Kunming City

    Kunming, Yunnan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.